Amphastar Pharmaceuticals, Inc. entered into a purchase agreement to issue and sell $300.0 million aggregate principal amount of 2.00% Convertible Senior Notes due 2029, with an option for the initial purchasers to purchase an additional $45.0 million aggregate principal amount of Notes.